According to IPO Early Insights,Recently, Yellwin announced the completion of a nearly 100-million-yuan B-round financing.Led by EF Capital, with Beishang Capital and Bohai Chuangfu following up, WinX Capital acted as the exclusive financial advisor. Through this round of financing, Yellwin will continue to strengthen its R&D innovation and market penetration capabilities in cardiovascular surgery and other extended fields, further consolidating its leading position.

Yellwin was founded in September 2021. Based on the founding team's extensive clinical experience, the company identifies clinical needs and combines them with the current state of relevant fields to develop multiple globally first, China-first, or market-gap-filling medical devices. Currently, the company has independently developed two major product lines: coronary surgery and critical care & extracorporeal circulation, encompassing nearly 10 products. Among these, the ultrasonic vascular flow measurement system, pulsatile left ventricular assist system, and dual-lumen jugular catheter are all China-first products. While focusing on its core business, Yellwin also possesses the ability to expand externally and integrate through mergers and acquisitions. In 2025, the company expanded into the DVT product line through acquisitions, which includes two innovative medical devices, both of which have entered the clinical trial registration stage.

Dr. Liu Jingjing, Partner of Efung Capital, stated that Yellwin, founded by an exceptional team of clinical medical experts and industry veterans, adopts a "medical-engineering integration" model to deeply understand and precisely address the core clinical challenges in cardiovascular surgery, offering full-process medical devices and solutions in areas such as coronary heart disease and heart failure diagnosis and treatment.

Established for less than five years, the company has built a gradient pipeline covering AI diagnostics, high-end innovative devices, and import-substitution products, demonstrating excellent systematic innovation capabilities driven by clinical needs. Its unique pulsatile interventional left ventricular assist device in China and other products possess significant clinical value.

"We firmly believe that Yellwin, with its solid clinical foundation, comprehensive product portfolio, and efficient transformation capabilities, will undoubtedly grow into a leading enterprise in the cardiovascular device field. This investment aims to support the company in accelerating product development and market expansion, jointly promoting the independent innovation and industrialization process of China's high-end medical devices."

Bohai Chuangfu stated that Yellwin is dedicated to building an innovative medical device R&D platform in the field of cardiac surgery. Relying on the team's clinical experience, it designs cardiac surgery products that better meet the needs of frontline clinical applications in China. Based on the complex and fragmented nature of the cardiovascular surgery industry, Yellwin has developed a product matrix combining short-term and long-term solutions, along with a strategic focus on distinctive flagship products. Its commercial model has been validated, and expectations are high for Yellwin to bring innovation and the localization of high-end cardiac surgical devices in China to new heights.

Zou Guowen, founding partner of Fortune Capital, stated: "It is an honor to have served Yellwin in multiple rounds of financing and to have witnessed one important milestone after another for Yellwin. From the golden combination of clinical experts and industry veterans, to the innovative model of integrating medicine and engineering, to a robust product pipeline with a tiered approach, as well as the ability to focus on core businesses while possessing strong capabilities for business expansion and M&A integration—Yellwin has proven its unique value to the market in less than five years. We are honored to have built this bridge between capital and high-quality projects, and we look forward to Yellwin seizing the momentum to further consolidate its leading position in cardiovascular surgery and other extended fields."